Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted Melphalan SCT and Adjuvant Thalidomide in AL Amyloidosis
NCT01527032Phase 2Completed
- Sponsor
- Food and Drug Administration
- Start
- Sep 2002
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of melphalan, thalidomide in amyloid light chain amyloidosis, sponsored by Food and Drug Administration. Started Sep 2002; status: completed.
02
Drugs
melphalanthalidomide
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT01527032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527032.